Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110643 · ClinicalTrials.gov registry record · Phase 2
Infrared Non-Cutting Laser Therapy for Acne
A Phase 2 study of Acne Vulgaris, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00110643 is a Phase 2 study of Acne Vulgaris that has completed, run by University of Michigan. The registered enrollment target is 50 participants, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00110643, a Phase 2 study of Acne Vulgaris, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin. In this study, we are interested in learning how well such a laser works to improve the symptoms of acne. The laser used in this particular study will be the CoolTouch II® laser, manufactured by ICN Photonics, Inc., and has not been FDA-approved for the treatment of acne.
Conditions Studied
Interventions
- DEVICE CoolTouch II laser
Study Locations (1)
Michigan
- University of Michigan Dermatology Department - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2003-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110643
The ClinicalTrials.gov registry entry for NCT00110643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (82% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which CoolTouch II laser is the first listed.
NCT00110643 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00110643 about?
NCT00110643 is a clinical study titled "Infrared Non-Cutting Laser Therapy for Acne". The purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin. In this study, we are interested in learning how well such a laser works to improve the symptoms of acne. The lase...
What is the current status of trial NCT00110643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2003-02. Estimated completion is 2005-12.
What conditions does trial NCT00110643 study?
This clinical trial studies the following conditions: Acne Vulgaris.
What interventions are being tested in trial NCT00110643?
The interventions under investigation include: CoolTouch II laser (DEVICE).
Who is sponsoring clinical trial NCT00110643?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00110643 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acne Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Moderate to Severe Acne Vulgaris With Photodynamic Therapy in Adults
ACTIVE NOT RECRUITING · Phase 2
-
Dose Range Study of CD5789 in Acne Vulgaris
COMPLETED · Phase 2
-
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
COMPLETED · Phase 2
-
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Patients With Skin Type V or IV With Acne Vulgaris
COMPLETED · Phase 2
-
Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris
COMPLETED · Phase 2
-
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.